Daniel Attias and Gimv continue their organic and external growth strategy in Hauts-de-France and Normandy, enabling Biolam – a group of medical laboratories – to exceed EUR 60 million in turnover (pro forma of the latest acquisitions).
Starting from scratch in 2019, Daniel Attias was supported by Gimv in his first MBI takeover of the Biolam group of laboratories in Amiens. Didier Thibaud joined in 2020 to strengthen the Biolam presence in Normandy. Today, this duo is pursuing an accelerated growth strategy. After four acquisitions and four laboratory creations in 2020, Biolam (www.groupebiolam.fr ) realised three new acquisitions over 2021. The group has consolidated its position in Normandy with the acquisition of Boyer Laboratories, contributing approximately EUR 8 million in additional turnover. In the Hauts-de-France region, Biolam acquired the Mine laboratories in the Valencienne region, where it began its growth by opening two laboratories (Marly and La Madeleine), as well as the acquisition of the Tabardel and Viart laboratory in Béthune.
In 2022, Biolam intends to continue its organic growth with the opening of 6 new laboratories, several acquisitions under negotiation and significant investments in the renewal of its industrial equipment, in Normandy as well as in the Hauts-de-France.
The success of this buy-and-build platform demonstrates once again that the Gimv Health & Care team, together with ambitious management teams, is expert in consolidation projects in Europe.
Gautier Lefebvre, Partner at Gimv, and Kevin Klein, Principal at Gimv, state: “We are impressed by the trajectory of Biolam, which, under the leadership of Daniel Attias and Didier Thibaud, continues to grow extremely fast while investing heavily in its teams and tools in order to build a high quality healthcare offering. This entrepreneurial adventure is a perfect illustration of our ability to support managers in rapid external growth strategies. Over the past two years, Gimv’s Health & Care team has completed 32 acquisitions via 6 build-up platforms.”
Daniel Attias, Chairman of the Biolam Group, says: “We have already exceeded the targets we initially set ourselves with the Gimv team, which is a sign of a very effective collaboration. We start 2022 with great ambitions in a sanitary context where our willingness to invest, our agility and the total engagement of our teams are more necessary than ever.”
